SS
Suman Sahadev Dumbre
About Suman Sahadev Dumbre
Data last updated:
Suman Sahadev Dumbre is a Director at Clinzone Clinical Research Services Private Limited (since 2014) and Designated Partner at Unity Medical Llp (since 2019). The companies operate in Healthcare and Business Services. The largest current company by reported revenue is Clinzone Clinical Research Services Private Limited at ₹16.9 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Clinzone Clinical Research Services Private Limited U74900PN2014PTC152841 | Director | 17 Oct 2014 | 2014 | ₹16.9 Lakh (FY 2025) | Active |
| Unity Medical Llp AAK-7646 | Designated Partner | 16 Dec 2019 | 2017 | Active |
Board colleagues of Suman Sahadev Dumbre
| Name | DIN | Company | Designation |
|---|---|---|---|
| Umesh Sahadev Dumbre | 03387083 | Clinzone Clinical Research Services Private Limited | Director |
| Jayshri Anil Pachange | 06969162 | Unity Medical Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Suman Sahadev Dumbre
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Suman Sahadev Dumbre
Suman Sahadev Dumbre currently holds 2 directorships: Clinzone Clinical Research Services Private Limited (Director, since 17 Oct 2014, revenue ₹16.9 Lakh (FY 2025)); Unity Medical Llp (Designated Partner, since 16 Dec 2019).
Suman Sahadev Dumbre was first appointed on 17 Oct 2014 as Director at Clinzone Clinical Research Services Private Limited. The most recent appointment on record is 16 Dec 2019 at Unity Medical Llp.
The current boards of Suman Sahadev Dumbre's companies include Umesh Sahadev Dumbre (Clinzone Clinical Research Services Private Limited), Jayshri Anil Pachange (Unity Medical Llp).